Total | Vascular surgeons | Orthopaedic surgeons | p-value | |
---|---|---|---|---|
Determining extent of infection prior to surgical treatment 1 | ||||
Based on international classification system | 13/49 (26.5%) | 9/29 (31.0%) | 4/20 (20.0%) | 2 |
Based on extent of erythema | 27/49 (55.1%) | 18/29 (62.1%) | 9/20 (45.0%) | |
Based on extent of skin with raised temps | 19/49 (38.8%) | 14/29 (48.3%) | 5/20 (25.0%) | |
Based on amount and type of wound exudate | 21/49 (42.9%) | 14/29 (48.3%) | 7/20 (35.0%) | |
Based on extent of swelling | 20/49 (40.8%) | 15/29 (51.7%) | 5/20 (25.0%) | |
Based on degree of tissue necrosis | 30/49 (61.2%) | 19/29 (65.5%) | 11/20 (55.0%) | |
Others | 18/49 (36.7%) | 6/29 (20.7%) | 12/20 (60.0%) | |
Wound sampling prior to surgical treatment | ||||
Tissue or bone biopsy | 17/49 (34.7%) | 4/29 (13.8%) | 13/20 (65.0%) | p < 0.001 3 |
Wound swab | 27/49 (55.1%) | 22/29 (75.9%) | 5/20 (25.0%) | |
Others | 5/49 (10.2%) | 3/29 (10.3%) | 2/20 (10.0%) | |
Guideline usage | ||||
Yes | 14/49 (28.6%) | 10/29 (34.5%) | 4/20 (7.4%) | P = 0.435 4 |
No | 35/49 (71.4%) | 19/29 (65.5%) | 16/20 (29.6%) | |
Antibiotic choice | ||||
Piperacillin/Tazobactam | 21/41 (51.2%) | 13/22 (59.1%) | 8/19 (42.1%) | p = 0.871 3 |
Amoxicillin/Clavulanic acid | 8/41 (19.5%) | 4/22 (18.2%) | 4/19 (21.1%) | |
Cefazolin | 5/41 (12.2%) | 2/22 (9.1%) | 3/19 (15.8%) | |
Defer to guidelines or infectious diseases | 5/41 (12.2%) | 2/22 (9.1%) | 3/19 (15.8%) | |
Other antibiotics | 2/41 (4.9%) | 1/22 (4.5%) | 1/19 (5.3%) | |
Antibiotic route | ||||
IV | 31/40 (77.5%) | 18/21 (85.7%) | 13/19 (68.4%) | p = 0.518 3 |
IV + Oral | 2/40 (5.0%) | 1/21 (4.8%) | 1/19 (5.3%) | |
Defer to guidelines or infectious diseases physicians | 5/40 (12.5%) | 2/21 (9.5%) | 3/19 (15.8%) | |
Others | 2/40 (5.0%) | 0/21 (0.0%) | 2/19 (10.5%) | |
Wound dressing selection 1 | ||||
Iodine-based dressings | 26/42 (61.9%) | 14/22 (63.6%) | 12/20 (60.0%) | 2 |
Betadine paint | 10/42 (23.8%) | 9/22 (40.9%) | 1/20 (5.0%) | |
Saline soaked packing | 19/42 (45.2%) | 12/22 (54.5%) | 7/20 (35.0%) | |
Betadine soaked packing | 13/42 (31.0%) | 10/22 (45.5%) | 3/20 (15.0%) | |
Chlorohexidine-based dressings | 1/42 (2.4%) | 0/22 (0.0%) | 1/20 (5.0%) | |
Silver-based dressings | 23/42 (54.8%) | 11/22 (50.0%) | 12/20 (60.0%) | |
Honey-based dressings | 1/42 (2.4%) | 0/22 (0.0%) | 1/20 (5.0%) | |
Negative pressure therapy | 38/42 (90.5%) | 19/22 (86.4%) | 19/20 (95.0%) | |
No dressing | 2/42 (4.8%) | 2/22 (9.1%) | 0/20 (0.0%) | |
Others | 9/42 (21.4%) | 8/22 (36.4%) | 1/20 (5.0%) | |
Wound closure after debridement 1 | ||||
Healing by primary closure | 19/42 (45.2%) | 10/22 (45.5%) | 9/20 (45.0%) | 2 |
Healing by delayed primary closure | 27/42 (64.3%) | 13/22 (59.1%) | 14/20 (70.0%) | |
Superficial skin graft | 18/42 (42.9%) | 13/22 (59.1%) | 5/20 (25.0%) | |
Healing by secondary intention | 39/42 (92.9%) | 20/22 (90.9%) | 19/20 (95.0%) |